Beijing, China and Cambridge, Massachusetts, USA September 13 / PRNewswire-Asianet /-- BeiGene, Ltd. (Nasdaq: BGNE; SEHK: 06160) is a global biopharmaceutical company focused on the development and commercialization of innovative drugs worldwide. The company announced today that it will present its clinical results and subgroup analysis of its rich product line in the field of lung cancer treatment at the 2021 European Society of Oncology (ESMO) annual meeting.

Ben Yong, MD, chief medical officer of BeiGene, Ltd. 's immune oncology, said: "with the company's rich immune tumor product line, we have continued to make significant research progress, including seven phase 3 clinical trials in the field of non-small cell lung cancer. With the deepening of our understanding of the clinical effects of drugs, we are accelerating Baise'an.^®The development process of new combination therapies in the field of lung cancer, including the company's own research and development of strong anti-TIGIT antibody ociperlimab, as well as external cooperation in the development of drugs under development, such as sitravatinib combination therapy. In addition, our scientists are exploring Bazeam.^®A new mode of combined use of drugs in the field of lung cancer and other solid tumors. At the same time, with the promotion of cooperation with Novartis, Baze'an^®We can take advantage of Novartis's advantage in oncology drug pipeline to explore more possibilities of combination therapy. We look forward to exploring the therapeutic potential of this differentiated immune checkpoint inhibitor to benefit more patients around the world through the exploration of combination therapy for patients with different tumor types. "

For more information about BeiGene, Ltd. 's R & D and ESMO annual meeting activities, please visit https://beigenemedical.eu/.

Bai Ze'an^®Extensive joint treatment research projects in the field of lung cancer

BeiGene, Ltd. is trying to explore Baise'an.^®Multiple mechanisms of combined use of drugs to improve the targeting effect of PD-1 pathway in order to improve the clinical effect or overcome the drug resistance related to disease progression.

In the treatment of non-small cell lung cancer (NSCLC), many patients who were relieved after receiving frontline anti-PD-1 antibody eventually relapsed due to drug resistance. BeiGene, Ltd. is studying Bazean by working with Mirati Therapeutics.^®In combination with sitravatinib, sitravatinib is a broad-spectrum selective tyrosine kinase inhibitor that is expected to overcome immune tolerance by reversing the immunosuppressive tumor microenvironment. BeiGene, Ltd. is conducting phase 3 trials of the new combination therapy in the NSCLC field, and will present the clinical results of his ongoing phase 1b trial in metastatic NSCLC patients, including newly diagnosed and refractory or resistant to anti-PD- (L) 1 treatment, at the 2021 ESMO annual meeting.

Another innovative combination therapy research carried out by BeiGene, Ltd. in the field of lung cancer is Bai Ze'an.^®A combination with ociperlimab. Ociperlimab is a potent anti-TIGIT antibody under development with complete Fc segment function. At present, this combination therapy is in phase III clinical trials. TIGIT is a co-inhibitory immune checkpoint receptor, which is expressed in a variety of immune cells. Recently, it has been found that TIGIT can be used as a new therapeutic target, and combined with PD-1 may further inhibit the anti-tumor immune response. Bai Ze'an^®Extensive combination therapy in the field of lung cancer also includes combination with PI3K δ inhibitor BGB-10188, anti-TIM-3 antibody BGB-A425 and chemotherapy.

Continue to expand driven by excellent scientific research strength and clinical insightNSCLCDomain development

In recent years, although the global treatment in the field of NSCLC has made some progress, but as a high incidence type of cancer, there are still a large number of unmet treatment needs in clinical treatment. BeiGene, Ltd. is currently evaluating Baise'an in a comprehensive NSCLC project.^®The project includes more than 10 clinical trials covering patients from the early stage to the posterior line.

In order to further explore the impact of different patient characteristics on treatment results, BeiGene, Ltd. 's immuno-oncology team analyzed the clinical results of the NSCLC trial from the aspects of region, disease stage, smoking status, and the use of biomarkers.

BeiGene, Ltd. recently presented the results of a subgroup analysis of the RATIONALE 307 trial at the World Lung Cancer Congress (WCLC) in 2021. The subgroup analysis showed that regardless of PD-L1 expression, blood tumor mutation load (TMB), tissue TMB and disease stage (IIIB or IV stage).^®Combination chemotherapy showed consistent survival benefits in newly treated patients with squamous non-small cell lung cancer.

At the 2021 ESMO Annual meeting, BeiGene, Ltd. will also report the additional analysis of smokers and non-smokers in phase 3 clinical trials of RATIONALE 304and RATIONALE 307 first-line NSCLC.

In addition, BeiGene, Ltd. is exploring Baise'an.^®As a potential early treatment option, phase 3 of the global trial RATIONALE 315 is under way to explore Bazeam.^®Application in the field of neoadjuvant or adjuvant therapy.

BeiGene, Ltd. in2021年ESMOElectronic posters displayed at the annual meeting